PDCD1 and metastatic melanoma: Single cell profiling of tumor-infiltrating immune cells from 32 metastatic melanoma patients treated with anti-PD-1- and/or CTLA-4 antibodies identified two major CD8+ T cell states associated with clinical outcome [50].